

Press Release

ProStrakan Group plc

ProStrakan Announces FDA Acceptance of Abstral Filing

Galashiels, UK. 6th October 2009 - ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces that its New Drug Application (NDA) filing for Abstral has been accepted for review by the US Food and Drug Administration (FDA).

Abstral is a new, rapidly disintegrating, sub-lingual formulation of fentanyl, a long-established opioid used for the management of episodes of breakthrough pain experienced by cancer patients who are already receiving opioid analgesics for their chronic pain.

Subject to successful completion of the US approval process, ProStrakan plans to launch Abstral in the second half of 2010 in the US, where the company currently markets Sancuso, its anti-nausea and vomiting patch for chemotherapy patients.

Commenting on today's announcement, Dr Wilson Totten, ProStrakan's Chief Executive, said:

"The successful filing of the NDA for Abstral in the US is a further achievement in our strategy of establishing our US-based oncology supportive care franchise."

Ends

Further enquiries:

ProStrakan

Dr Wilson Totten, Chief Executive
Allan Watson, Chief Financial Officer

Tel: +44 (0) 1896 664000

Brunswick Group

Jon Coles / Justine McIlroy

Tel: +44 (0) 20 7404 5959

Trout Group (for US investor enquiries)

Gitanjali Jain Ogawa

Tel: +1 (646) 378-2949